The bill establishes a Prescription Drug Affordability Board within the Department of Insurance, tasked with identifying up to ten prescription drugs annually that incur significant healthcare costs to the state. The board will require drug manufacturers to report specific information, including wholesale acquisition cost increases and research and development expenditures, to ensure transparency in drug pricing. The bill defines key terms such as "enrollee" and "rebate," and mandates that the information submitted by manufacturers aligns with their annual reports to the Securities and Exchange Commission. Additionally, the bill emphasizes the confidentiality of the data provided, protecting it from public disclosure to maintain the competitive nature of the information.

Amendments adopted in the conference report include the acceptance of certain House Committee amendments while rejecting others that would have limited the information required from manufacturers and altered reporting obligations. The bill also removes a sunset provision, ensuring its ongoing enforcement. The effective date for the provisions is set for January 1, 2027, contingent upon the enactment of related legislation. Overall, the bill aims to enhance oversight of prescription drug pricing and promote affordability for consumers in Louisiana.

Statutes affected:
SB401 Original: 44:1(B)(11)
SB401 Engrossed: 44:1(B)(11), 22:1870(B)(5)
SB401 Reengrossed: 44:1(B)(11), 22:1870(B)(5)
SB401 Enrolled: 44:1(B)(11), 22:1870(B)(5)